MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pepin, M. C.
Right arrow Articles by Barden, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pepin, M. C.
Right arrow Articles by Barden, N.

Increased glucocorticoid receptor gene promoter activity after antidepressant treatment

MC Pepin, MV Govindan and N Barden

Molecular Psychogenetics Laboratory, Research Center, Ste Foy, Quebec, Canada.

We have tested the hypothesis that antidepressants affect the expression of the glucocorticoid receptor gene, by looking at glucocorticoid receptor gene promoter activity, glucocorticoid receptor mRNA levels, and glucocorticoid-binding activity after treatment of different cell lines with desipramine. Treatment of LTK- cells or Neuro 2A cells with desipramine produced a 50-200% increase in chloramphenicol acetyltransferase activity transcribed from a 2.7- kilobase glucocorticoid receptor gene promoter region. In cell lines derived from both neuronal and non-neuronal sources, glucocorticoid receptor mRNA concentration doubled after desipramine treatment, and this was associated with a 2-fold higher functional glucocorticoid binding capacity and increased glucocorticoid sensitivity, as measured with the reporter plasmid pMMTVCAT. Antidepressant-induced increases in glucocorticoid receptor gene promoter activity, glucocorticoid receptor mRNA levels, and functional glucocorticoid binding activity suggest a novel mechanism of action for these drugs on the hypothalamic-pituitary- adrenal axis.

Volume 41, Issue 6, pp. 1016-1022, 06/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
R. McQUADE and A. H. Y. YOUNG
Future therapeutic targets in mood disorders: the glucocorticoid receptor
The British Journal of Psychiatry, November 1, 2000; 177(5): 390 - 395.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. A. Slotkin, D. B. Miller, F. Fumagalli, E. C. McCook, J. Zhang, G. Bissette, and F. J. Seidler
Modeling Geriatric Depression in Animals: Biochemical and Behavioral Effects of Olfactory Bulbectomy in Young Versus Aged Rats
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 334 - 345.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
C. M. Pariante, B. D. Pearce, T. L. Pisell, M. J. Owens, and A. H. Miller
Steroid-Independent Translocation of the Glucocorticoid Receptor by the Antidepressant Desipramine
Mol. Pharmacol., October 1, 1997; 52(4): 571 - 581.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
N. Warriar, N. Page, and M. V. Govindan
Expression of Human Glucocorticoid Receptor Gene and Interaction of Nuclear Proteins with the Transcriptional Control Element
J. Biol. Chem., August 2, 1996; 271(31): 18662 - 18671.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1992 by the American Society for Pharmacology and Experimental Therapeutics